Overview

  • Product name
    Anti-Tau (phospho S214) antibody [EPR1884(2)]
    See all Tau primary antibodies
  • Description
    Rabbit monoclonal [EPR1884(2)] to Tau (phospho S214)
  • Host species
    Rabbit
  • Tested applications
    Suitable for: Dot blot, IHC-P, WBmore details
    Unsuitable for: Flow Cyt,ICC or IP
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    corresponding to Human Tau (phospho S214).
    Database link: P10636

  • Positive control
    • WB:SH-SY5Y and C57 mouse cerebral cortex cell lysates. IHC: Human brain, normal spleen, normal kidney, cervical carcinoma and glioma tissues; Mouse brain tissue. Dot Blot:Tau (phospho S214) phospho peptide and Tau non-phospho peptide.
  • General notes

    A trial size is available to purchase for this antibody.

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab170892 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Dot blot 1/1000.
IHC-P 1/100 - 1/250. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
WB 1/1000 - 1/10000. Predicted molecular weight: 78 kDa.
  • Application notes
    Is unsuitable for Flow Cyt,ICC or IP.
  • Target

    • Function
      Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
    • Tissue specificity
      Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.
    • Involvement in disease
      Note=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).
      Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.
      Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.
      Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.
      Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.
    • Sequence similarities
      Contains 4 Tau/MAP repeats.
    • Developmental stage
      Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
    • Domain
      The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
    • Post-translational
      modifications
      Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.
      Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.
      Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
    • Cellular localization
      Cytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
    • Information by UniProt
    • Database links
    • Form
      There are 9 isoforms produced by alternative splicing.
    • Alternative names
      • AI413597 antibody
      • AW045860 antibody
      • DDPAC antibody
      • FLJ31424 antibody
      • FTDP 17 antibody
      • G protein beta1/gamma2 subunit interacting factor 1 antibody
      • MAPT antibody
      • MAPTL antibody
      • MGC134287 antibody
      • MGC138549 antibody
      • MGC156663 antibody
      • Microtubule associated protein tau antibody
      • Microtubule associated protein tau isoform 4 antibody
      • Microtubule-associated protein tau antibody
      • MSTD antibody
      • Mtapt antibody
      • MTBT1 antibody
      • MTBT2 antibody
      • Neurofibrillary tangle protein antibody
      • Paired helical filament tau antibody
      • Paired helical filament-tau antibody
      • PHF tau antibody
      • PHF-tau antibody
      • PPND antibody
      • PPP1R103 antibody
      • Protein phosphatase 1, regulatory subunit 103 antibody
      • pTau antibody
      • RNPTAU antibody
      • TAU antibody
      • TAU_HUMAN antibody
      • Tauopathy and respiratory failure, included antibody
      see all

    Images

    • Immunohistochemical analysis of paraffin-embedded Human glioma tissue labeling Tau (phospho S214) with ab170892 at 1/100 dilution.

    • All lanes : Anti-Tau (phospho S214) antibody [EPR1884(2)] (ab170892) at 1/1000 dilution

      Lane 1 : C57 mouse cerebral cortex whole cell lysates.
      Lane 2 : C57 mouse cerebral cortex whole cell lysates. The membrane was incubated with phosphatase.

      Lysates/proteins at 15 µg per lane.

      Secondary
      All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

      Predicted band size: 78 kDa
      Observed band size: 50-70 kDa
      why is the actual band size different from the predicted?


      Exposure time: 30 seconds


      Blocking/Diluting buffer and concentration: 5% NFDM/TBST

    • ab170892 showing +ve staining in Mouse brain tissue.

    • All lanes : Anti-Tau (phospho S214) antibody [EPR1884(2)] (ab170892) at 1/1000 dilution

      Lane 1 : SH-SY5Y cell lysates untreated
      Lane 2 : SH-SY5Y cell lysates treated with Okadic acid + Calyculin A.

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : Goat anti-rabbit HRP at 1/2000 dilution

      Predicted band size: 78 kDa

    • Dot blot analysis of Tau (phospho S214) phospho peptide (Lane 1) and Tau non-phospho peptide (Lane 2) labeling Tau (phospho S214) with ab170892 at a dilution of 1/1000. ab97051 (Peroxidase conjugated goat anti-rabbit IgG) (H+L) at 1/100 000 was used as the secondary antibody.

      Blocking and diluting buffer: 5% NFDM/TBST.

      Exposure time: 3 minutes.

    • Immunohistochemical analysis of paraffin-embedded Human brain tissue labeling Tau (phospho S214) with ab170892 at 1/100 dilution.

    • ab170892 showing -ve staining in Human normal spleen tissue.
    • ab170892 showing -ve staining in Human normal kidney tissue.
    • ab170892 showing -ve staining in Human cervical carcinoma tissue.

    References

    This product has been referenced in:
    • Fujita K  et al. Targeting Tyro3 ameliorates a model of PGRN-mutant FTLD-TDP via tau-mediated synaptic pathology. Nat Commun 9:433 (2018). Read more (PubMed: 29382817) »
    • Wang T  et al. Involvement of Insulin Signaling Disturbances in Bisphenol A-Induced Alzheimer's Disease-like Neurotoxicity. Sci Rep 7:7497 (2017). Read more (PubMed: 28790390) »
    See all 3 Publications for this product

    Customer reviews and Q&As

    Abcam has not validated the combination of species/application used in this Abreview.
    Application
    Immunohistochemistry free floating
    Sample
    Human Tissue sections (Brain)
    Specification
    Brain

    Sumit Sarkar

    Verified customer

    Submitted Jun 02 2017

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up